Literature DB >> 33964138

SGLT2 inhibitors in cardiovascular medicine.

Fahimeh Varzideh1,2, Urna Kansakar1,2, Gaetano Santulli1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33964138      PMCID： PMC8488965          DOI： 10.1093/ehjcvp/pvab039

Source DB:  PubMed          Journal:  Eur Heart J Cardiovasc Pharmacother


× No keyword cloud information.
  5 in total

Review 1.  Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes.

Authors:  Rita R Kalyani
Journal:  N Engl J Med       Date:  2021-04-01       Impact factor: 91.245

2.  Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.

Authors:  John J V McMurray; Scott D Solomon; Silvio E Inzucchi; Lars Køber; Mikhail N Kosiborod; Felipe A Martinez; Piotr Ponikowski; Marc S Sabatine; Inder S Anand; Jan Bělohlávek; Michael Böhm; Chern-En Chiang; Vijay K Chopra; Rudolf A de Boer; Akshay S Desai; Mirta Diez; Jaroslaw Drozdz; Andrej Dukát; Junbo Ge; Jonathan G Howlett; Tzvetana Katova; Masafumi Kitakaze; Charlotta E A Ljungman; Béla Merkely; Jose C Nicolau; Eileen O'Meara; Mark C Petrie; Pham N Vinh; Morten Schou; Sergey Tereshchenko; Subodh Verma; Claes Held; David L DeMets; Kieran F Docherty; Pardeep S Jhund; Olof Bengtsson; Mikaela Sjöstrand; Anna-Maria Langkilde
Journal:  N Engl J Med       Date:  2019-09-19       Impact factor: 91.245

3.  Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.

Authors:  Bruce Neal; Vlado Perkovic; Kenneth W Mahaffey; Dick de Zeeuw; Greg Fulcher; Ngozi Erondu; Wayne Shaw; Gordon Law; Mehul Desai; David R Matthews
Journal:  N Engl J Med       Date:  2017-06-12       Impact factor: 91.245

4.  Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure.

Authors:  Deepak L Bhatt; Michael Szarek; P Gabriel Steg; Christopher P Cannon; Lawrence A Leiter; Darren K McGuire; Julia B Lewis; Matthew C Riddle; Adriaan A Voors; Marco Metra; Lars H Lund; Michel Komajda; Jeffrey M Testani; Christopher S Wilcox; Piotr Ponikowski; Renato D Lopes; Subodh Verma; Pablo Lapuerta; Bertram Pitt
Journal:  N Engl J Med       Date:  2020-11-16       Impact factor: 91.245

5.  Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.

Authors:  Milton Packer; Stefan D Anker; Javed Butler; Gerasimos Filippatos; Stuart J Pocock; Peter Carson; James Januzzi; Subodh Verma; Hiroyuki Tsutsui; Martina Brueckmann; Waheed Jamal; Karen Kimura; Janet Schnee; Cordula Zeller; Daniel Cotton; Edimar Bocchi; Michael Böhm; Dong-Ju Choi; Vijay Chopra; Eduardo Chuquiure; Nadia Giannetti; Stefan Janssens; Jian Zhang; Jose R Gonzalez Juanatey; Sanjay Kaul; Hans-Peter Brunner-La Rocca; Bela Merkely; Stephen J Nicholls; Sergio Perrone; Ileana Pina; Piotr Ponikowski; Naveed Sattar; Michele Senni; Marie-France Seronde; Jindrich Spinar; Iain Squire; Stefano Taddei; Christoph Wanner; Faiez Zannad
Journal:  N Engl J Med       Date:  2020-08-28       Impact factor: 176.079
  5 in total
  5 in total

Review 1.  Heart failure in diabetes.

Authors:  Stanislovas S Jankauskas; Urna Kansakar; Fahimeh Varzideh; Scott Wilson; Pasquale Mone; Angela Lombardi; Jessica Gambardella; Gaetano Santulli
Journal:  Metabolism       Date:  2021-10-08       Impact factor: 8.694

2.  Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry.

Authors:  Pasquale Paolisso; Luca Bergamaschi; Emanuele Barbato; Carmine Pizzi; Gaetano Santulli; Emanuele Gallinoro; Arturo Cesaro; Felice Gragnano; Celestino Sardu; Niya Mileva; Alberto Foà; Matteo Armillotta; Angelo Sansonetti; Sara Amicone; Andrea Impellizzeri; Gianni Casella; Ciro Mauro; Dobrin Vassilev; Raffaele Marfella; Paolo Calabrò
Journal:  Cardiovasc Diabetol       Date:  2022-05-15       Impact factor: 8.949

3.  Differences in outcomes of hospitalizations for heart failure after SGLT2 inhibitor treatment: effect modification by atherosclerotic cardiovascular disease.

Authors:  Shih-Chieh Shao; Kai-Cheng Chang; Swu-Jane Lin; Shang-Hung Chang; Ming-Jui Hung; Yuk-Ying Chan; Edward Chia-Cheng Lai
Journal:  Cardiovasc Diabetol       Date:  2021-10-23       Impact factor: 9.951

Review 4.  Current and Emerging Classes of Pharmacological Agents for the Management of Hypertension.

Authors:  Utkarsh Ojha; Sanjay Ruddaraju; Navukkarasu Sabapathy; Varun Ravindran; Pitchaya Worapongsatitaya; Jeesanul Haq; Raihan Mohammed; Vinod Patel
Journal:  Am J Cardiovasc Drugs       Date:  2021-12-08       Impact factor: 3.283

5.  Interaction Between Non-Insulin Glucose-Lowering Medication and Exercise in Type 2 Diabetes Mellitus - New Findings on SGLT2 Inhibitors.

Authors:  Christian Brinkmann
Journal:  Front Endocrinol (Lausanne)       Date:  2021-07-15       Impact factor: 5.555
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.